Literature DB >> 28712563

Trends in comorbidity in patients hospitalised for cardiovascular disease.

Josefien Buddeke1, Michiel L Bots2, Ineke van Dis3, Anho Liem4, Frank L J Visseren5, Ilonca Vaartjes6.   

Abstract

BACKGROUND: We determined trends over time in cardiovascular and non-cardiovascular comorbidity in patients hospitalised for cardiovascular disease (CVD).
METHODS: The Dutch nationwide hospital register was used to identify patients hospitalised for CVD during 2000-2010. Comorbidity was defined as a previous hospital admission for CVD other than the index CVD, cancer, diabetes, musculoskeletal and connective tissue disorders, respiratory disorders, thyroid gland disorders, kidney disorders and dementia in the five years previous to hospital admittance for the index CVD. Trends were calculated in strata of age and sex and for different types of CVD: coronary heart disease (CHD), cerebrovascular disease (CVA), heart failure (HF) and peripheral arterial disease (PAD).
RESULTS: We identified 2,397,773 admissions for CVD between 2000 and 2010. Comorbidity was present in 38%. In HF, PAD, CHD and CVA this was 54%, 46%, 40%, and 32%, respectively. Between 2000 and 2010, the percentage of patients with comorbidity increased (+1.1%), this increase was most pronounced in patients ≥75years (+3.0%). Cardiovascular disease was the most frequent comorbid condition, though became less prevalent over time (men -5%; women: -2%), whereas non-cardiovascular comorbidity increased in men (+4%), and remained similar in women (-1%). Cancer was the most common non-cardiovascular comorbid condition and increased in men and women (men: +5%; women: +4%).
CONCLUSIONS: Comorbid conditions are highly prevalent in patients hospitalised for CVD, especially HF and PAD patients. In older patients, prevalences increased over time. Cardiovascular diseases were the most common comorbid condition, though the prevalence decreased over the study period whereas the prevalence of cancer increased.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Comorbidity; Epidemiology; Trends

Mesh:

Year:  2017        PMID: 28712563     DOI: 10.1016/j.ijcard.2017.06.106

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data.

Authors:  Josefien Buddeke; Michiel L Bots; Ineke van Dis; Frank Lj Visseren; Monika Hollander; François G Schellevis; Ilonca Vaartjes
Journal:  Br J Gen Pract       Date:  2019-05-07       Impact factor: 5.386

2.  Comorbidities complicating heart failure: changes over the last 15 years.

Authors:  Elles M Screever; Martje H L van der Wal; Dirk J van Veldhuisen; Tiny Jaarsma; Astrid Koops; Kuna S van Dijk; Janke Warink-Riemersma; Jenifer E Coster; B Daan Westenbrink; Peter van der Meer; Rudolf A de Boer; Wouter C Meijers
Journal:  Clin Res Cardiol       Date:  2022-08-17       Impact factor: 6.138

3.  In-patient care trends in peripheral artery disease in the German healthcare system over the past decade.

Authors:  Josua A Decker; Akos Varga-Szemes; U Joseph Schoepf; Tilman Emrich; Florian Schwarz; Thomas J Kroencke; Christian Scheurig-Muenkler
Journal:  Eur Radiol       Date:  2021-10-13       Impact factor: 7.034

4.  Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.

Authors:  Tian-Tian Ma; Ian C K Wong; Kenneth K C Man; Yang Chen; Thomas Crake; Muhiddin A Ozkor; Ling-Qing Ding; Zi-Xuan Wang; Lin Zhang; Li Wei
Journal:  PLoS One       Date:  2019-01-18       Impact factor: 3.240

5.  Readmission and mortality in patients ≥70 years with acute myocardial infarction or heart failure in the Netherlands: a retrospective cohort study of incidences and changes in risk factors over time.

Authors:  P Jepma; G Ter Riet; M van Rijn; C H M Latour; R J G Peters; W J M Scholte Op Reimer; B M Buurman
Journal:  Neth Heart J       Date:  2019-03       Impact factor: 2.380

6.  Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk for cardiovascular disease: rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic.

Authors:  Gideon B Valstar; Sophie H Bots; Floor Groepenhoff; Aisha Gohar; Frans H Rutten; Tim Leiner; Maarten Jan Maria Cramer; Arco J Teske; Leonardo P Suciadi; Roxana Menken; Gerard Pasterkamp; Folkert W Asselbergs; Leonard Hofstra; Michael L Bots; Hester M den Ruijter
Journal:  BMJ Open       Date:  2019-06-05       Impact factor: 2.692

7.  Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims.

Authors:  Alessandro Battaggia; Angelo Avogaro; Gian Paolo Fadini; Barbara Di Camillo; Alessandro Guazzo; Enrico Longato; Mario Luca Morieri; Giovanni Sparacino; Bruno Franco-Novelletto; Maurizio Cancian; Massimo Fusello; Lara Tramontan
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

8.  Identification of a pleiotropic effect of ADIPOQ on cardiac dysfunction and Alzheimer's disease based on genetic evidence and health care records.

Authors:  Hyojung Paik; Junehawk Lee; Chan-Seok Jeong; Jun Sung Park; Jeong Ho Lee; Nadav Rappoport; Younghoon Kim; Hee-Young Sohn; Chulman Jo; Jimin Kim; Seong Beom Cho
Journal:  Transl Psychiatry       Date:  2022-09-16       Impact factor: 7.989

9.  Association of Functional Characteristics and Physiotherapy with COVID-19 Mortality in Intensive Care Unit in Inpatients with Cardiovascular Diseases.

Authors:  Chiara Andrade Silva; Agnaldo José Lopes; Jannis Papathanasiou; Luis Felipe Fonseca Reis; Arthur Sá Ferreira
Journal:  Medicina (Kaunas)       Date:  2022-06-18       Impact factor: 2.948

Review 10.  Epidemiology of heart failure.

Authors:  Amy Groenewegen; Frans H Rutten; Arend Mosterd; Arno W Hoes
Journal:  Eur J Heart Fail       Date:  2020-06-01       Impact factor: 15.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.